Live Feeds
● TRACKER Updated 24d ago Β· 48 sources tracked

Trump Administration Finalizes Plan to Lower Drug Prices in Medicare

The Centers for Medicare & Medicaid Services has finalized the Global Benchmark for Efficient Drug Pricing Model, a mandatory initiative to reduce Medicare spending and beneficiary out-of-pocket costs. This move comes ahead of Medicare open enrollment for 2027 coverage, which begins on October 29 and runs through December 7. The initiative aims to make prescription drugs more affordable for Medicare recipients.

πŸŽ™οΈ

Listen to Live Briefing

Real-time synthesized voice briefing Β· Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (55)
⚑ Key Developments & Real-Time Context
Text size:
  • βœ“ The Centers for Medicare & Medicaid Services has finalized the Global Benchmark for Efficient Drug Pricing Model.
  • βœ“ Medicare open enrollment for 2027 coverage begins on October 29 and runs through December 7.
πŸ›‘οΈ Source Corroboration: 48 independent reporting domains (80% confidence) ⏱ Read time: ~2 min

What changed

The Centers for Medicare & Medicaid Services finalized the Global Benchmark for Efficient Drug Pricing Model.

Live updates

  1. Trump Administration Finalizes Plan to Lower Drug Prices in Medicare

    The Centers for Medicare & Medicaid Services has finalized the Global Benchmark for Efficient Drug Pricing Model, a mandatory initiative to reduce Medicare spending and beneficiary out-of-pocket costs. This move comes ahead of Medicare open enrollment for 2027 coverage, which begins on October 29 and runs through December 7. The initiative aims to make prescription drugs more affordable for Medicare recipients.

    Why it matters

    The Trump administration faces scrutiny over pharmaceutical investments. The new initiative is expected to impact Medicare Part B drug pricing. The changes may influence the healthcare industry and affect providers and patients.

    What is confirmed

    • The Centers for Medicare & Medicaid Services has finalized the Global Benchmark for Efficient Drug Pricing Model.
    • Medicare open enrollment for 2027 coverage begins on October 29 and runs through December 7.

    What to watch next

    • Impact of the Global Benchmark for Efficient Drug Pricing Model on Medicare spending and beneficiary out-of-pocket costs
    • Reactions from pharmaceutical companies and healthcare providers
    • Effectiveness of the initiative in reducing prescription drug prices during the 2027 coverage period
    Sources used for this update (5)
    1. www.ajmc.com β€” Alternative Payment Models | Compendium | Page 10 | AJMC
    2. www.billing-coding.com β€” CMS Finalizes GLOBE Model: What Medicare Part B Drug Pricing ...
    3. abcnews.com β€” What to know about changes to Medicare plans as open ...
    4. www.breitbart.com β€” Indiana Articles - Breitbart
    5. www.americanactionforum.org β€” Epic's New Prescription Marketplace: Greater Price Transparency, Lower Costs? - AAF
    confidence 80%
  2. Trump Administration Finalizes Plan to Lower Drug Prices in Medicare

    The Centers for Medicare & Medicaid Services has finalized the Global Benchmark for Efficient Drug Pricing Model, a mandatory initiative to reduce Medicare spending and beneficiary out-of-pocket costs. This move comes as the Trump administration faces scrutiny over pharmaceutical investments and ahead of Medicare open enrollment for 2027 coverage, which begins on October 29 and runs through December 7.

    Why it matters

    The Trump administration has been under scrutiny over pharmaceutical investments, with a Democratic report alleging that President Trump increased holdings in drugmakers that benefited from Medicare price negotiation exemptions. The administration has reached pricing agreements with some pharmaceutical companies, including Novo Nordisk and Eli Lilly, for certain medications. The finalized plan aims to reduce Medicare spending and beneficiary out-of-pocket costs.

    What is confirmed

    • The Centers for Medicare & Medicaid Services finalized the Global Benchmark for Efficient Drug Pricing Model to reduce Medicare spending and beneficiary out-of-pocket costs.
    • Medicare open enrollment for 2027 coverage begins on October 29 and runs through December 7.
    • The Trump administration has reached pricing agreements with Novo Nordisk and Eli Lilly for GLP-1 medications.

    Still unconfirmed

    • President Trump increased holdings in drugmakers that benefited from Medicare price negotiation exemptions.

    What to watch next

    • The impact of the Global Benchmark for Efficient Drug Pricing Model on Medicare spending and beneficiary out-of-pocket costs
    • The outcome of Medicare open enrollment for 2027 coverage
    • Further developments in the Trump administration's efforts to address pharmaceutical pricing
    Sources used for this update (5)
    1. finance.yahoo.com β€” Yahoo Finance - Stock Market Live, Quotes, Business & Finance News
    2. en.wikipedia.org β€” Donald Trump - Wikipedia
    3. gardnermagazine.com β€” Weekly Briefing – Gardner Magazine – Gardner News Magazine: Local News & Articles in Gardner MA
    4. www.mondaq.com β€” Departments Finalize Transparency In Coverage Rules: What Health Plans And Issuers Need To Know - Healthcare - United States
    5. www.foxnews.com β€” Trump supporters reveal what worries them most as GOP fights ...
    confidence 90%
  3. CMS Finalizes GLOBE Model to Lower Medicare Part B Drug Costs

    The Centers for Medicare & Medicaid Services finalized the Global Benchmark for Efficient Drug Pricing Model to reduce Medicare spending and beneficiary out-of-pocket costs. This mandatory CMS Innovation Center initiative arrives as the Trump administration faces scrutiny over pharmaceutical investments. While the administration has reached pricing agreements with Novo Nordisk and Eli Lilly for GLP-1 medications, a Democratic report alleges President Trump increased holdings in drugmakers that benefited from Medicare price negotiation exemptions. Medicare open enrollment for 2027 coverage begins this Thursday and runs through December 7.

    Why it matters

    The GLOBE model aims to lower costs for Part B drugs during a period of high voter anger over healthcare expenses. This occurs alongside claims that the president's pharmaceutical portfolio grew from $1.7 million in 2024 to $56.2 million by late 2025. Maryland Governor Wes Moore has proposed linking state costs to these negotiated Medicare prices.

    What is confirmed

    • The Centers for Medicare & Medicaid Services finalized the Global Benchmark for Efficient Drug Pricing Model.
    • The GLOBE model is a mandatory CMS Innovation Center initiative to reduce Medicare spending and beneficiary out-of-pocket costs.
    • Medicare open enrollment for 2027 coverage starts Thursday and ends December 7.
    • A report from congressional Democrats found Trump's pharmaceutical stock holdings grew from a maximum reported value of $1.7 million in 2024 to as much as $56.2 million at the end of 2025.

    Still unconfirmed

    • President Trump increased investments in pharmaceutical firms that benefited from a Republican-backed law shielding medications from Medicare price negotiations.

    What to watch next

    • Implementation details of the GLOBE model for Part B drugs
    • Official response from the White House regarding pharmaceutical stock growth
    • Outcome of Medicare open enrollment for 2027 plans
    Sources used for this update (5)
    1. www.forbes.com β€” Download The Forbes App
    2. www.pbs.org β€” Democrats say Trump increased investments in drugmakers that ...
    3. www.asge.org β€” CMS Finalizes GLOBE Model to Lower Medicare Part B Drug Costs
    4. www.steveharveyfm.com β€” Medicare Open Enrollment Begins, 2027 Plan Changes Announced
    5. vinnews.com β€” Trump Increased Investments in Drugmakers Benefiting From ...
    confidence 95%
  4. Maryland Seeks Medicare Drug Pricing Ties as Trump Deals Move Forward

    Maryland Governor Wes Moore wants to connect state prescription costs to Medicare negotiated pricing while crediting Donald Trump for maintaining the program. Meanwhile, Eli Lilly and Novo Nordisk signed a pricing agreement with the Trump administration regarding GLP-1 medications for diabetes and obesity. A Democratic report released Friday by the Joint Economic Committee minority arm shows Trump pharmaceutical stock holdings grew from a maximum reported value of $1.7 million in 2024 to as much as $56.2 million at the end of 2025. Republicans are campaigning on presidential boasts about drug prices amid voter anger over healthcare costs.

    Why it matters

    The Trump administration faces an ongoing legal challenge from the pharmaceutical industry's leading trade group over its Medicare pricing model that benchmarks costs against 18 developed nations. The policy allows manufacturers who sign separate voluntary deals to bypass the standard benchmark rules. This structure has drawn scrutiny from congressional Democrats regarding administration investments in participating drugmakers.

    What is confirmed

    • Gov. Wes Moore wants Maryland to tie state drug costs to Medicare's negotiated prices and credited Trump for keeping the program running.
    • Trump's pharmaceutical stock holdings grew from a maximum reported value of $1.7 million in 2024 to as much as $56.2 million at the end of 2025, according to a report released Friday by the Joint Economic Committee's minority arm.
    • Novo Nordisk and Eli Lilly signed a pricing agreement with the Trump administration on GLP-1 drugs for diabetes and obesity.

    Still unconfirmed

    • The Trump administration's Medicare pricing model will apply to as few as four drugmakers due to voluntary deal exemptions.

    What to watch next

    • Further legal developments in the Pharmaceutical Research and Manufacturers of America lawsuit against Health Secretary Robert in the US District Court for the District of Columbia.
    • Additional state-level adoption of Medicare-negotiated drug prices following Maryland's push.
    Sources used for this update (6)
    1. hoodline.com β€” Moore Wants Maryland to Use Medicare Drug Price Deals - Hoodline
    2. www.latimes.com β€” Trump increased investments in drugmakers that benefited from ...
    3. pharmaphorum.com β€” Novo, Lilly sign MFN pricing deal with Trump administration
    4. www.lassennews.com β€” AARP reveals seven changes coming to Medicare in 2026
    5. 828newsnow.com β€” Asheville design panel backs 8-story Drury hotel - Asheville's 828 News NOW
    6. www.thebulwark.com β€” Trump Tells One Health Care Story. The Facts Tell Another. - Substack,The Bulwark
    confidence 95%
  5. Pharma Lobby Sues Trump Over Medicare Drug Price Rule

    The pharmaceutical industry's leading trade group sued the Trump administration on October 7 to invalidate a new Medicare drug pricing model. Filed by the Pharmaceutical Research and Manufacturers of America in the US District Court for the District of Columbia against Health Secretary Robert, the lawsuit claims the GLOBE rule is an illegal overreach by the government. The policy benchmarks US Medicare Part B prescription costs against prices paid in 18 other developed nations. However, the CMS plan features a limited reach, waiving manufacturers who sign separate voluntary deals and potentially applying to as few as four drugmakers.

    Why it matters

    The lawsuit challenges a core enforcement mechanism of the administration's aggressive push to curb healthcare costs for expensive cancer and autoimmune medications. While the government maintains the system will mirror most favored nation pricing used abroad, pharmaceutical advocates argue the regulation exceeds legal authority. CMS has structured the pilot to exclude companies striking separate voluntary pricing agreements with the White House.

    What is confirmed

    • The Pharmaceutical Research and Manufacturers of America filed a lawsuit on October 7 against Health Secretary Robert in the US District Court for the District of Columbia.
    • The lawsuit aims to invalidate the GLOBE rule, which benchmarks US Medicare Part B drug prices against costs in 18 other developed countries.
    • CMS plans to waive the rule for manufacturers that sign separate voluntary deals with the White House, meaning the pilot could apply to as few as four drugmakers.

    What to watch next

    • Judicial rulings from the US District Court for the District of Columbia regarding the legality of the GLOBE rule.
    • Additional participation or withdrawals by pharmaceutical companies regarding voluntary price deals with the White House.
    Sources used for this update (12)
    1. floridapolitics.com β€” Diagnosis for 10.5.26: Checking the pulse of Florida healthcare news and policy
    2. www.aol.com β€” Pharma lobby sues Trump administration over Medicare drug price cuts - AOL
    3. www.hawaiitribune-herald.com β€” Pharma lobby sues Trump administration over Medicare drug price cuts - Hawaii Tribune-Herald
    4. arynews.tv β€” Pharma lobby sues Trump administration over Medicare drug price cuts - ARY News
    5. www.yahoo.com β€” β€˜Daily Show’ Finds Major Flaw in Trump’s Crisis Plan
    6. www.cms.gov β€” New Regulations Make It Easier to Find, Compare, and Report Healthcare Pricing and Coverage Information |....
    7. www.cms.gov β€” Transparency in Coverage Final Rules (CMS 9882-F) | CMS
    8. medicaldialogues.in β€” PhRMA Challenges Trump's GLOBE Rule on Medicare Drug Prices, Calls It Illegal Overreach - Medical Dialogu....
    9. www.lawcommentary.com β€” Drugmakers Sue to Block Trump Medicare Plan Tying Drug Costs ...
    10. welltica.com β€” Trump just locked in lower drug prices - welltica.com
    11. hoodline.com β€” TrumpRx Drug Prices: Analysis Finds Mixed Results vs. World
    12. govtschemes.org β€” Medicare 2027 Part D Premium: What CMS Has Announced So Far
    confidence 100%
  6. Trump Administration Finalizes Medicare Drug Model and Price Transparency Rules

    The Trump administration finalized a mandatory Medicare Part B payment model on October 2, 2026, alongside new price transparency rules issued by HHS, Labor, and Treasury departments. The Global Benchmark for Efficient Drug Pricing model benchmarks prescription costs against prices in Australia and 18 other developed countries, though the pilot is now limited to four companies and yields far less savings than originally pitched. Meanwhile, the concurrent transparency overhaul requires health insurers and employer-sponsored plans to provide standardized pricing information and remove clutter from cost disclosures.

    Why it matters

    The administration is pursuing simultaneous healthcare reforms targeting prescription drug costs and insurance market transparency. While employers cheered the changes requiring insurers to open their books, the scaled-back Medicare pilot allows pharmaceutical companies to escape steeper price cuts. This dual approach aims to increase pricing clarity across the healthcare sector while narrowing the initial economic scope of federal drug price interventions.

    What is confirmed

    • The Centers for Medicare and Medicaid Services officially finalized the Global Benchmark for Efficient Drug Pricing model on October 2, 2026.
    • The HHS, Labor, and Treasury departments finalized a rule to strip out junk cluttering cost disclosures and require standardized pricing information.

    Still unconfirmed

    • The pilot payment rule for Medicare treatments administered in doctor offices is expected to impact just a handful of drugmakers.
    • Employers cheered the final transparency changes, which represent a mixed bag for insurers.

    What to watch next

    • Implementation outcomes of the four-company Medicare payment model test group
    • Response from health insurers and employers regarding the standardized price transparency reporting rules
    Sources used for this update (4)
    1. www.newsweek.com β€” New Trump Transparency Rules For Health Insurance: How You Could Benefit
    2. www.healthcaredive.com β€” Trump administration revamps insurer price transparency reporting | Healthcare Dive
    3. www.medicaleconomics.com β€” β€˜The game’s over’ β€” Trump administration pushes for more health care price transparency | Medical....
    4. news.bloomberglaw.com β€” Pharma Escapes Steep Price Cuts in Trump’s Latest Medicare Plan - Bloomberg Law News
    confidence 90%
  7. Trump Administration Finalizes GLOBE Drug Pricing Model for Medicare

    The Trump administration finalized a mandatory drug payment model for Medicare Part B that benchmarks prescription costs against prices in Australia and 18 other developed countries. The Global Benchmark for Efficient Drug Pricing model was officially finalized by the Centers for Medicare and Medicaid Services on October 2, 2026. However, the final version has been significantly scaled down from initial projections. Projected Medicare savings have fallen sharply compared to original estimates, leaving the program with a much narrower economic scope and a test group limited to four companies.

    Why it matters

    The administration aims to tackle high prescription costs by aligning what Medicare Part B pays with international price benchmarks. Previous proposals projected substantially higher financial returns, but revisions reduced the scope of the rule. The dramatic drop in projected savings highlights the scaling back of the administration's broader pricing agenda.

    What is confirmed

    • The Centers for Medicare and Medicaid Services finalized the Global Benchmark for Efficient Drug Pricing model on October 2, 2026.
    • The mandatory drug payment model benchmarks pricing against Australia and 18 other countries.

    Still unconfirmed

    • Projected Medicare savings under the finalized GLOBE rule have fallen to $440 million or $298 million, down from an initial $11.9 billion proposal.

    What to watch next

    • Implementation of the four-company test under the GLOBE model
    • Legal challenges regarding the economic case and legal theory of the finalized rule
    Sources used for this update (18)
    1. gardnermagazine.com β€” Greater Gardner MA News – September 2026 – Gardner News Magazine: Local News & Articles in Gardner MA
    2. WSJ β€” Trump Administration Finalizes Plan to Lower Drug Prices in Medicare
    3. STAT β€” Trump’s watered-down Medicare drug pricing rule saves 96% less than initial proposal
    4. Yahoo β€” What Medicaid’s New Payment Model Means For Your Prescriptions
    5. CBC β€” What Trump's 'most favoured nation' drug pricing policy might mean for Canadians
    6. FirstWord Pharma β€” CMS finalises narrower GLOBE model for Medicare Part B drugs
    7. PharmaDispatch β€” US announces formal plan that benchmarks pricing against Australia and 18 other countries
    8. Fierce Healthcare β€” CMS finalizes model that aims to bring most-favored nation pricing to Part B
    9. Endpoints News β€” CMS finalizes GLOBE rule as projected Medicare savings fall from $11.9B to $440M
    10. www.newsbreak.com β€” Ford fends off Hyundai to retain No. 3 U.S. sales position in third quarter - NewsBreak
    11. www.devdiscourse.com β€” Reuters Health News Summary | International
    12. www.americanactionforum.org β€” GLOBE’s Narrowing Economic Case and Questionable Legal Theory - AAF
    confidence 95%
πŸ“Š

Community Sentiment: How do you assess this situation?

Voice your perspective Β· Real-time aggregated sentiment from the Live Feeds community